HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors

December 06, 2023 00:29:56
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors
COR2ED - Oncology Medical Conversation
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors

Dec 06 2023 | 00:29:56

/

Show Notes

In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or unresectable HCC and explain the immunomodulation rationale to combine it with immune checkpoint inhibitor.

Combination approach has been validated recently with the atezolizumab+bevacizumab combination being the new standard of care in 1L setting for advanced HCC patients. In the context of advanced HCC, both experts share their view about the dosing approach with VEGFR-TKI and provide insight to handle the dosing when combining with PD-1 inhibitor.

Both experts reiterate that biomarkers are urgently needed in HCC and summarize the current stratification of patients used to predict the response with VEGFR-TKI monotherapy or in immunotherapy combination. Finally, they emphasize that pre-habilitation of HCC patients is key to make the HCC patient fit for the best available treatment option.

Other Episodes

Episode

November 08, 2024 00:25:50
Episode Cover

BRAF-mutated CRC: testing to treatment

Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available...

Listen

Episode

December 06, 2023 00:21:28
Episode Cover

Upper GI cancer: Update from ESMO 2022 - Part 2

This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022.  Dr Sam Klempner (Massachusetts General Hospital, Boston, USA) and...

Listen

Episode

December 06, 2023 00:23:31
Episode Cover

Prostate cancer: Shared decision-making in nmCRPC

Brenda Martone, a nurse practitioner at Northwestern Medicine in Chicago Illinois and Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in...

Listen